Federal Register of Legislation - Australian Government

Primary content

PB 42 of 2019 Determinations/Health as made
This instrument determines originator brands of pharmaceutical items for two drugs moving to the F2 formulary.
Administered by: Health
Registered 31 May 2019
Tabling HistoryDate
Tabled HR02-Jul-2019
Tabled Senate02-Jul-2019
To be repealed 17 Sep 2019
Repealed by Division 1 of Part 3 of Chapter 3 of the Legislation Act 2003

PB 42 of 2019

National Health (Originator Brand) Amendment Determination 2019 (No. 4)

National Health Act 1953

I, THEA DANIEL, Assistant Secretary, Pricing and PBS Policy Branch, Technology Assessment and Access Division, Department of Health, delegate of the Minister for Health, make this Determination under subsection 99ADB (6B) of the National Health Act 1953.

Dated       24  May 2019

 

 

 

 

 

 

THEA DANIEL

Assistant Secretary

Pricing and PBS Policy Branch

Technology Assessment and Access Division

Department of Health



1              Name of Determination

                 (1)     This Determination is the National Health (Originator Brand) Amendment Determination 2019 (No. 4).

(2)     This Determination may also be cited as PB 42 of 2019.

2              Commencement

                This Determination commences on 1 June 2019.

3              Amendments to PB 100 of 2015

                Schedule 1 amends the National Health (Originator Brand) Determination 2015 (PB 100 of 2015).


Schedule 1     Amendments

(section 3)

[1]                   Schedule 1 (after table item 82)

insert:

82A

Fenofibrate

Lipidil

 

 

[2]                   Schedule 1 (after table item 225)

insert:

225A

Teriflunomide

Aubagio